Adjunctive echinocandin for HIV-negative Pneumocystis pneumonia
This report is preliminary based on evalauble papers identifed.
Overview
This site presents an interim meta-analysis of adjunctive echinocandin/caspofungin plus trimethoprim-sulfamethoxazole (TMP-SMX) versus TMP-SMX monotherapy for all-cause mortality in HIV-negative / immunocompromised adults with Pneumocystis jirovecii pneumonia (PCP/PJP). It corresponds to the PROSPERO-registered review question on combination and adjunctive treatment regimens, and reports both a frequentist and a Bayesian synthesis of the same six source-verified studies.
Headline finding
Pooling the six source-verified studies, adjunctive echinocandin shows a possible but inconclusive mortality benefit versus monotherapy — the interval includes no effect under both frameworks.
| Analysis | Studies | Pooled OR (95% interval) |
|---|---|---|
| Bayesian sensitivity (primary reporting) | 6 | 0.76 (0.43–1.37) |
| Frequentist random-effects (REML) | 6 | 0.75 (0.42–1.36) |
| Bayesian primary (in-hospital / ~30-day) | 3 | 0.78 (0.31–1.93) |
An OR below 1 favours combination therapy.
What was verified
- Tian2020 excluded — an HIV-positive cohort that had been misclassified in the machine-draft extraction.
- Qi2025 / Yanmeng2026 de-duplicated — the same PUMCH cohort; the full-cohort comparison (not the ventilated subgroup) was used.
- Counts were source-checked against the original full texts for every included study.
Language / lingua
Use the EN / IT buttons at the top-right of any page to switch between English and Italian (automatic Google machine translation; English is the source of record). The toggle requires an external web browser with internet access.